Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

New genetic risk factors for depression have been identified across all major global populations for the first time, allowing ...

Harmony Biosciences Holdings, Inc. today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Avadel Pharmaceuticals reported revenue targets for its narcolepsy treatment Lumryz that missed analyst estimates. The company said it expects net product revenue to be $240 million to $260 million in ...

Avadel said it expects Lumryz to generate about $50 million in revenue for the fourth quarter, missing current analyst forecasts by $3.7 million, and $169 million for the full year, $1.7 million shy ...

as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The FDA approval of LUMRYZ was supported by results from REST-ON, a ...

LUMRYZ™ is Avadel’s FDA-approved treatment for narcolepsy, being the first once-at-bedtime oxybate for related symptoms. Disclaimer: This is an AI-generated summary of a press release ...